{
 "updated": "2026-11-02",
 "about": "AI 药物发现相关的收购、合并、私有化和团队 / 平台收购，按宣布日期从新到旧；layer 对应 layers.json 的 code。price 只写公司公布的或标「报道称」，未披露不估算。target_in_map = 被买的公司在图谱里。confidence：A = 公司公告 / SEC 或两家独立来源，B = 一家可靠媒体，C = 聚合站或转述。网页版：/acquisitions",
 "deals": [
  {
   "announced": "2026-10-27",
   "closed": "2026-07（据报道；Anthropic 10-27 才披露）",
   "buyer": "Anthropic",
   "target": "Mithril Medicine（1 名全职员工）",
   "layer": "l1",
   "layer_name": "前沿实验室的生命科学线",
   "price": "未披露（The Information 称未披露条款）",
   "price_disclosed": false,
   "after": "创始人 Cody Tranbarger 加入 Anthropic；两个罕见肌营养不良双特异性抗体项目成为 Anthropic 自研药物开发的第一批项目，据称已有小鼠阶段概念验证，人体试验最早 2028 年末。",
   "confidence": "A",
   "target_in_map": false,
   "src": [
    "https://www.anthropic.com/research/early-progress-drug-development",
    "https://www.rdworldonline.com/anthropic-acquires-mithril-medicine-one-person-biotech/",
    "https://thenextweb.com/news/anthropic-mithril-acquisition-claude-drug-development"
   ],
   "kind": "收购",
   "note": "同日 Anthropic 公布与 BigHat、BMS、Divergence Labs、Enveda、Generate、The Column Group 六家的研究合作早期结果。"
  },
  {
   "announced": "2026-10-19",
   "closed": "已收购（OpenAI 公告用过去时；交割日未披露）",
   "buyer": "OpenAI",
   "target": "Orchestra Bio",
   "layer": "l2",
   "layer_name": "AI 科学家与科研代理",
   "price": "未披露",
   "price_disclosed": false,
   "after": "团队与平台并入 OpenAI 生命科学线 Rosalind（GPT-Rosalind、Rosalind Workbench）；做药物开发项目协调的 AI agent。",
   "confidence": "A",
   "target_in_map": false,
   "src": [
    "https://openai.com/zh-Hant/index/openai-to-acquire-orchestra-bio/",
    "https://drug-dev.com/openai-acquires-orchestra-bio-to-connect-ai-research-with-drug-development-workflows/",
    "https://eu.36kr.com/en/p/4035266653230212"
   ],
   "kind": "收购",
   "note": "Orchestra 不设计分子，做研发项目管理。公告页日期 10-19（美国时间），多家媒体记 10-20。TechCrunch 经 ANTARA 转述称其 2025 年融资约 2000 万美元（二手）。"
  },
  {
   "announced": "2026-07-20",
   "closed": "待交割（预期 2026 年末或 2027 年初）",
   "buyer": "Tempus AI",
   "target": "Personalis",
   "layer": "t2",
   "layer_name": "专有数据资产",
   "price": "公布 $16.25/股，企业价值约 $15 亿（扣除 Tempus 已持股），股票加可选现金",
   "price_disclosed": true,
   "after": "交割后并入 Tempus（Personalis 为肿瘤 MRD 检测与基因组数据公司）。",
   "confidence": "A",
   "target_in_map": false,
   "src": [
    "https://investors.tempus.com/news-releases/news-release-details/tempus-acquire-personalis-more-tightly-integrating-molecular",
    "https://markets.businessinsider.com/news/stocks/ai-daily-tempus-ai-to-acquire-personalis-at-enterprise-value-of-1-5b-1036343451"
   ],
   "kind": "收购",
   "note": "边界案例：标的主业是基因组检测，买方是 AI 数据公司，按买方数据资产归 t2。需股东批准，双方各 $7680 万终止费。"
  },
  {
   "announced": "2026-06-16",
   "closed": "2026-10-06",
   "buyer": "Altaris（医疗私募）",
   "target": "Simulations Plus",
   "layer": "m4",
   "layer_name": "计算化学与模拟软件",
   "price": "公布 $18.50/股，约 $3.75 亿，全现金",
   "price_disclosed": true,
   "after": "摘牌；与 Altaris 旗下 Chemical Computing Group 合并，做生物模拟药物发现与开发平台。",
   "confidence": "A",
   "target_in_map": true,
   "src": [
    "https://www.nasdaq.com/press-release/simulations-plus-be-acquired-altaris-approximately-375-million-2026-06-16",
    "https://www.businesswirenews.com/news/home/20261006258966/en/Simulations-Plus-Announces-Completion-of-Acquisition-by-Altaris"
   ],
   "kind": "私有化",
   "note": "动脉网记 06-25，公司稿为 06-16。"
  },
  {
   "announced": "2026-05-17",
   "closed": "2026-07-02（SEC 10-Q）",
   "buyer": "Liminatus Pharma（纳斯达克 LIMN）",
   "target": "InnocsAI LLC",
   "layer": "m1",
   "layer_name": "结构与共折叠",
   "price": "股票支付，发行 11,188,729 股普通股与 158,881 股可转非表决优先股；S&P Capital IQ 经 MarketScreener 报约 $3.2 亿（未核一手）",
   "price_disclosed": false,
   "after": "InnocsAI 并入 Liminatus；公司另披露持续经营与纳斯达克合规风险。",
   "confidence": "A",
   "target_in_map": false,
   "src": [
    "https://www.sec.gov/Archives/edgar/data/1971387/000110465926097304/limn-20260630x10q.htm",
    "https://www.marketscreener.com/news/liminatus-pharma-inc-completed-the-acquisition-of-innocsai-llc-ce7f5ed9dd8bf025",
    "https://www.metatrader.com/tr/symbols/nasdaq/limn/documents/595782-current-report-q2-fy2026"
   ],
   "kind": "收购",
   "note": "宣布日 2026-05-17 来自 R1/MarketScreener，未在 SEC 文件中直接核到。交割日以 10-Q 为准（R1 误作 07-01）。"
  },
  {
   "announced": "2026-05-06",
   "closed": "待交割（预期 2026 下半年）",
   "buyer": "Roche（罗氏诊断部门）",
   "target": "PathAI",
   "layer": "c2",
   "layer_name": "试验设计与数字孪生",
   "price": "公布 $7.5 亿预付 + 最高 $3 亿里程碑（合计最高 $10.5 亿）",
   "price_disclosed": true,
   "after": "交割后并入罗氏诊断；AISight 影像管理系统在其肿瘤诊断平台上全球推广。",
   "confidence": "A",
   "target_in_map": false,
   "src": [
    "https://www.lw.com/en/news/2026/05/latham-watkins-advises-pathai-on-acquisition-by-roche",
    "https://www.biopharmadive.com/news/roche-to-acquire-digital-pathology-firm-pathai-in-deal-potentially-worth-ov/819592/",
    "https://mobile.labmedica.com/industry-news/articles/294810360/roche-to-acquire-pathai-for-up-to-105-billion-to-strengthen-ai-diagnostics-portfolio.amp.html"
   ],
   "kind": "收购",
   "note": "边界案例：数字病理 + 伴随诊断 AI，主业偏诊断；因含临床试验入组与生物标志物发现业务而收。动脉网记 05-07，Latham 与 BioPharma Dive 为 05-06（美国时间）。"
  },
  {
   "announced": "2026-04-02",
   "closed": "未披露（媒体称已收购）",
   "buyer": "Anthropic",
   "target": "Coefficient Bio（成立约 8 个月，不到 10 人）",
   "layer": "l1",
   "layer_name": "前沿实验室的生命科学线",
   "price": "报道称超 4 亿美元，全股票（The Information；Anthropic 未公开确认）",
   "price_disclosed": false,
   "after": "团队并入 Anthropic 医疗与生命科学部门。",
   "confidence": "B",
   "target_in_map": false,
   "src": [
    "https://www.nasdaq.com/articles/anthropic-inks-us-400-million-deal-ai-biotech-startup-coefficient-bio",
    "https://ctol.digital/news/anthropic-acquires-coefficient-bio-400m/",
    "https://www.ice.it/it/news/notizie-dal-mondo/302991"
   ],
   "kind": "团队收购",
   "note": "日期有 04-02 / 04-07 两说，取最早报道。意大利外贸机构页称团队多为 Genentech Prescient Design 前研究员（单源）。价格只见于媒体，不升 A。"
  },
  {
   "announced": "2026-02-25",
   "closed": "预期 2026 Q2；交割日未核",
   "buyer": "IQVIA",
   "target": "Charles River 欧洲 Discovery Services 部分资产（5 个站点，含 AI 小分子发现能力）",
   "layer": "w2",
   "layer_name": "AI 赋能的 CRO/CRDMO",
   "price": "公布约 $1.45 亿现金 + 最多 $1000 万附加支付",
   "price_disclosed": true,
   "after": "从 Charles River 剥离；Charles River 同日另行出售 CDMO 与细胞业务给 GI Partners（$6240 万）。",
   "confidence": "A",
   "target_in_map": false,
   "src": [
    "https://www.fiercebiotech.com/cro/charles-river-sells-manufacturing-and-discovery-businesses-fulfill-promised-strategic-pivot",
    "https://in.marketscreener.com/news/iqvia-holdings-inc-nyse-iqv-entered-into-a-definitive-agreement-to-acquire-european-discovery-s-ce7e5cd8d980f227",
    "https://www.hannessnellman.com/selected-reference/hannes-snellman-advised-charles-river-laboratories-inc-in-the-divestment-of-certain-european-discovery-services-assets-to-iqvia-holdings-inc/"
   ],
   "kind": "资产/平台收购",
   "note": "边界案例：买卖双方都是 CRO，被卖的是体外发现服务与 AI 小分子发现站点。R1 里两源冲突的附加支付已核：MarketScreener 与 Hannes Snellman 均为最多 $1000 万。"
  },
  {
   "announced": "2026-01-13",
   "closed": "2026-01-13（S&P Capital IQ 记为完成）",
   "buyer": "AstraZeneca",
   "target": "Modella AI（波士顿，病理基础模型与 agent）",
   "layer": "m3",
   "layer_name": "试验设计与数字孪生",
   "price": "未披露",
   "price_disclosed": false,
   "after": "并入阿斯利康肿瘤研发，用于临床开发与生物标志物发现；此前 2025-07 已合作。",
   "confidence": "A",
   "target_in_map": true,
   "src": [
    "https://www.reuters.com/pt/negocio/WJUO3BM3L5M23AVOGMEXEXQXGI-2026-01-13/",
    "https://www.americanpharmaceuticalreview.com/1315-News/623686-AstraZeneca-to-Acquire-Modella-AI-to-Strengthen-AI-Driven-Oncology-R-D/",
    "https://in.marketscreener.com/news/astrazeneca-plc-acquired-modella-ai-inc-ce7e58d8dd89f521"
   ],
   "kind": "收购",
   "note": "边界案例：病理 AI，按用途归 c2；Reuters 写「同意收购」，完成日只见 S&P Capital IQ 一家。"
  },
  {
   "announced": "2026-01-12",
   "closed": "预计 2026-01 下旬（公司稿）；实际交割日未核",
   "buyer": "insitro",
   "target": "CombinAbleAI（以色列 Rehovot，抗体 in-silico 设计）",
   "layer": "a2",
   "layer_name": "抗体与蛋白药",
   "price": "未披露",
   "price_disclosed": false,
   "after": "成为 insitro 以色列研发中心，同时推出 TherML 全模态平台（小分子、寡核苷酸、抗体）。",
   "confidence": "A",
   "target_in_map": false,
   "src": [
    "https://www.insitro.com/news/combinabletherml/",
    "https://www.drugtargetreview.com/insitro-expands-ai-drug-discovery-with-combinableai-acquisition/682272.article",
    "https://www.ivc-online.com/Google-Card?id=49C830F3-90F0-F011-B81B-00505695CD29&type=1"
   ],
   "kind": "收购",
   "note": "卖方 Aion Labs（Mergr 记为剥离）。"
  },
  {
   "announced": "2025-11-20",
   "closed": "2025-11-20（8-K 事件日；公司稿 11-21）",
   "buyer": "Shuttle Pharmaceuticals（纳斯达克 SHPH）",
   "target": "Molecule.ai（加拿大，1542770 BC Ltd.）",
   "layer": "m1",
   "layer_name": "结构与共折叠",
   "price": "10 月 LOI 公布约 $1000 万现金加股票，含里程碑；最终价格未核",
   "price_disclosed": true,
   "after": "资产与负债并入 Shuttle。",
   "confidence": "A",
   "target_in_map": false,
   "src": [
    "https://www.nasdaq.com/press-release/shuttle-pharmaceuticals-acquire-ai-molecular-modeling-and-predictive-analytics",
    "https://www.americanpharmaceuticalreview.com/1315-News/622210-Shuttle-Pharma-to-Acquire-Molecule-ai-in-10-Million-AI-Powered-R-D-Deal/",
    "https://www.metatrader.com/zh/symbols/nasdaq/shph/documents/75149-current-report-q4-fy2025"
   ],
   "kind": "资产/平台收购",
   "note": "小市值上市公司，LOI 在 2025-10-20/21 宣布。标的为 AI 分子建模平台。"
  },
  {
   "announced": "2025-11-05",
   "closed": "未核实（Reuters 2026-05 称已含收购）",
   "buyer": "Biohub（Chan Zuckerberg 旗下研究机构）",
   "target": "EvolutionaryScale",
   "layer": "m2",
   "layer_name": "蛋白生成模型",
   "price": "未披露",
   "price_disclosed": false,
   "after": "EvolutionaryScale 团队并入 Biohub，联合创始人 Alex Rives 任 Biohub 科学负责人；2026-05 Biohub 发布基于 ESM 第四代的蛋白生物学世界模型。",
   "confidence": "A",
   "target_in_map": true,
   "src": [
    "https://biohub.org/news/ai-biology-cure-disease/",
    "https://www.eurekalert.org/news-releases/1104835",
    "https://tech.yahoo.com/ai/meta-ai/articles/zuckerbergs-philanthropic-venture-unveils-ai-120751145.html"
   ],
   "kind": "团队收购",
   "note": "Biohub 官方稿措辞是「团队加入」，SF Chronicle 写 acquire the team，Reuters 写 acquisition。"
  },
  {
   "announced": "2025-08-22",
   "closed": "2025-08-22（S&P Capital IQ）",
   "buyer": "Tempus AI",
   "target": "Paige",
   "layer": "t2",
   "layer_name": "专有数据资产",
   "price": "公布 $8125 万，主要以 Tempus 股票支付，另承接 Paige 的 Microsoft Azure 承诺",
   "price_disclosed": true,
   "after": "并入 Tempus，带来约 700 万张数字病理切片及临床分子数据。",
   "confidence": "A",
   "target_in_map": false,
   "src": [
    "https://www.paulhastings.com/news/paul-hastings-advises-paige-ai-in-usd81-25-million-acquisition-by-tempus-ai",
    "https://www.nasdaq.com/articles/tempus-key-acquisitions-strengthen-its-ai-healthcare-leadership",
    "https://in.marketscreener.com/news/tempus-ai-inc-acquired-paige-ai-inc-in-a-transaction-valued-at-81-2-million-ce7c50dbd88df121"
   ],
   "kind": "收购",
   "note": "R1 提到 Tempus 年报摘要另有 $1.015 亿口径，只见聚合站摘要，未能核对；公告口径四源一致为 $8125 万。"
  },
  {
   "announced": "2025-06-12",
   "closed": "2025-06-12（港交所公告为完成公告）",
   "buyer": "晶泰控股 XtalPi",
   "target": "Liverpool ChiroChem（LCC，英国）",
   "layer": "w1",
   "layer_name": "自动化/自驱动实验室",
   "price": "未披露（公告称各项适用百分比率低于 5%，未构成须予公布交易）",
   "price_disclosed": false,
   "after": "成为晶泰全资子公司，并入「AI + 机器人」自主实验平台；PACE 手性化学平台，2026-09 与斯坦福签药物发现合作。",
   "confidence": "A",
   "target_in_map": false,
   "src": [
    "https://data.eastmoney.com/notices/detail/02228/AN202506121689229081.html",
    "https://www.xtalpi.com/%e6%99%b6%e6%b3%b0%e7%a7%91%e6%8a%80%e5%ae%a3%e5%b8%83%e5%ae%8c%e6%88%90%e5%af%b9%e8%8b%b1%e5%9b%bd%e5%88%a9%e7%89%a9%e6%b5%a6lcc%e5%8c%96%e5%ad%a6%e6%8a%80%e6%9c%af%e5%85%ac%e5%8f%b8%e7%9a%84/",
    "http://stock.10jqka.com.cn/hks/20260918/c680056409.shtml"
   ],
   "kind": "收购",
   "note": "只有完成公告，宣布日与完成日同为 2025-06-12。"
  },
  {
   "announced": "2025-04-02",
   "closed": "2025-07-02",
   "buyer": "Siemens",
   "target": "Dotmatics（Insight Partners 旗下）",
   "layer": "m4",
   "layer_name": "计算化学与模拟软件",
   "price": "公布企业价值 $51 亿",
   "price_disclosed": true,
   "after": "并入 Siemens Digital Industries Software，加入 Xcelerator 生命科学组合。",
   "confidence": "A",
   "target_in_map": true,
   "src": [
    "https://news.siemens.com/th-th/siemens-dotmatics/",
    "https://w1.siemens.com.cn/press/NewsDetail_en.aspx?ColumnId=9&ArticleId=21877",
    "https://www.nasdaq.com/articles/dotmatics-agrees-be-acquired-siemens-51-bln"
   ],
   "kind": "收购",
   "note": "边界案例：研发数据与科学软件平台，非纯 AI。Siemens 原计划交割在 2026 财年上半年，实际提前完成。"
  },
  {
   "announced": "2025-03-11",
   "closed": "2025-03-11（宣布时已收购）",
   "buyer": "Tempus AI",
   "target": "Deep 6 AI",
   "layer": "c1",
   "layer_name": "招募与匹配",
   "price": "未披露",
   "price_disclosed": false,
   "after": "整合 Tempus 临床试验患者匹配业务，覆盖 750+ 站点。",
   "confidence": "A",
   "target_in_map": true,
   "src": [
    "https://www.precisionmedicineonline.com/precision-oncology/tempus-ai-acquires-clinical-trial-patient-matching-firm-deep-6-ai",
    "https://investors.tempus.com/node/8306/pdf"
   ],
   "kind": "收购"
  },
  {
   "announced": "2025-02-05",
   "closed": "2025-03-12（合并生效；03-13 摘牌）",
   "buyer": "Osaka Holdings（BenevolentAI 执行主席 Ken Mulvany 的载体）",
   "target": "BenevolentAI",
   "layer": "a1",
   "layer_name": "小分子",
   "price": "未披露（股份按 1:1 换成 Osaka Holdings 股份；公告无现金对价）",
   "price_disclosed": false,
   "after": "BenevolentAI 并入 Osaka Holdings 后改名 BenevolentAI S.A.，非上市，继续运营。",
   "confidence": "A",
   "target_in_map": true,
   "src": [
    "https://www.benevolent.com/news-and-media/press-releases-and-in-media/egm-results-announcement/",
    "https://www.iex.nl/Forum/Upload/2025/15680745.pdf"
   ],
   "kind": "私有化",
   "note": "2025-02-05 是董事会批准合并条款的日期，对外宣布日未找到。EGM 赞成票超 95%。"
  },
  {
   "announced": "2024-11-04",
   "closed": "2025-02-03",
   "buyer": "Tempus AI",
   "target": "Ambry Genetics",
   "layer": "t2",
   "layer_name": "专有数据资产",
   "price": "公布 $6 亿（$3.75 亿现金 + $2.25 亿股票）",
   "price_disclosed": true,
   "after": "并入 Tempus 诊断业务。",
   "confidence": "A",
   "target_in_map": false,
   "src": [
    "https://www.captodayonline.com/tag/tempus-ai/",
    "https://stockanalysis.com/stocks/tem/filings/3467506/"
   ],
   "kind": "收购",
   "note": "边界案例：遗传检测实验室，按买方的基因组数据资产归 t2。本条沿用 R1 的出处，二次未重开原文。"
  },
  {
   "announced": "2024-08-08",
   "closed": "2024-11-20",
   "buyer": "Recursion",
   "target": "Exscientia",
   "layer": "a1",
   "layer_name": "小分子",
   "price": "报道称约 $6.88 亿，全股票（Reuters）",
   "price_disclosed": true,
   "after": "成为 Recursion 全资子公司并摘牌；合并后 2025 年砍项目、裁员。",
   "confidence": "A",
   "target_in_map": true,
   "src": [
    "https://www.reuters.com/markets/deals/biotech-firm-recursion-buy-smaller-peer-exscientia-688-million-2024-08-08/",
    "https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2024-565",
    "https://www.biopharmatrend.com/post/894-recursion-pharmaceuticals-acquires-exscientia-in-688-million-all-stock-deal/"
   ],
   "kind": "合并",
   "note": "Reuters 与 Nasdaq Trader 交割公告互相印证。裁员比例只见二手综述，未单独核。"
  },
  {
   "announced": "2024-07-09",
   "closed": "2024-10-02",
   "buyer": "Certara",
   "target": "Chemaxon（匈牙利）",
   "layer": "m4",
   "layer_name": "计算化学与模拟软件",
   "price": "公布 $9000 万现金",
   "price_disclosed": true,
   "after": "并入 Certara，进入发现阶段生物模拟；产品接入 D360 与 Simcyp。",
   "confidence": "A",
   "target_in_map": false,
   "src": [
    "https://content-archive.fast-edgar.com/20240709/AMB2H22C8Z22TJZZ2HZM2ZZZBKKGH2Y2Z266/tm2418257d3_ex99-1.htm",
    "https://www.nasdaq.com/press-release/certara-completes-acquisition-chemaxon-2024-10-02",
    "https://ir.certara.com/static-files/4579c7ba-08e6-4a05-83a3-75431c0cae3b"
   ],
   "kind": "收购",
   "note": "R1 曾记「同日交割、价格未查到」，两项都已更正（Mergr 来源作废）。"
  },
  {
   "announced": "2024-07-08",
   "closed": "2024-07-08（公司稿称已收购）",
   "buyer": "Iktos",
   "target": "Synsight（法国）",
   "layer": "w1",
   "layer_name": "自动化/自驱动实验室",
   "price": "未披露",
   "price_disclosed": false,
   "after": "并入 Iktos，补上自动化生物测试环节，与 Iktos Robotics 合成平台闭环。",
   "confidence": "A",
   "target_in_map": false,
   "src": [
    "https://www.globenewswire.com/fr/news-release/2024/07/08/2909388/0/en/Iktos-acquires-Synsight-a-life-sciences-technology-company-specializing-in-protein-protein-and-RNA-protein-interactions-targeted-drug-discovery.html",
    "https://drug-dev.com/iktos-acquires-synsight-a-company-specializing-in-protein-protein-rna-protein-interactions-targeted-drug-discovery/"
   ],
   "kind": "收购",
   "note": "R1 为信度 B（CB Insights 片段），已用 GlobeNewswire 公司稿升级。"
  },
  {
   "announced": "2024-02-28",
   "closed": "2024-02-28（公司稿称已收购）",
   "buyer": "Ginkgo Bioworks",
   "target": "Reverie Labs 的基础设施与软件资产（含 4 名 AI 团队成员）",
   "layer": "m1",
   "layer_name": "结构与共折叠",
   "price": "未披露",
   "price_disclosed": false,
   "after": "并入 Ginkgo AI/ML 发现服务，用于训练大规模生物基础模型。",
   "confidence": "A",
   "target_in_map": false,
   "src": [
    "https://ayondo.com/de/feed/broadcast/x/prnw?p=6302",
    "https://news.yaozh.com/archive/42117"
   ],
   "kind": "资产/平台收购",
   "note": "买下的是资产与团队，不是整个公司。Reverie 是 AI 小分子公司。同日 Ginkgo 另买了 Patch Biosciences 与 Proof Diagnostics。"
  },
  {
   "announced": "2024-02-28",
   "closed": "2024-02-28（据智药局转述）",
   "buyer": "Ginkgo Bioworks",
   "target": "Patch Biosciences",
   "layer": "a3",
   "layer_name": "新模态",
   "price": "未披露",
   "price_disclosed": false,
   "after": "并入 Ginkgo，补 AI 设计基因药物及下游检测能力。",
   "confidence": "B",
   "target_in_map": false,
   "src": [
    "https://pharmaphorum.com/news/ginkgo-bioworks-scales-again-ma-frenzy",
    "https://news.yaozh.com/archive/42117"
   ],
   "kind": "收购",
   "note": "只见 pharmaphorum 与智药局两家摘要，未打开 Ginkgo 原稿，不升 A。"
  },
  {
   "announced": "2023-12-12",
   "closed": "2023-12-12",
   "buyer": "Certara",
   "target": "Applied BioMath",
   "layer": "m4",
   "layer_name": "计算化学与模拟软件",
   "price": "10-K 记估计总对价约 $3659.4 万",
   "price_disclosed": true,
   "after": "并入 Certara 的 QSP 建模业务。",
   "confidence": "A",
   "target_in_map": false,
   "src": [
    "https://ir.certara.com/static-files/5cc9c5c0-d987-4925-b322-d600137239c8"
   ],
   "kind": "收购",
   "note": "边界案例：量化系统药理建模，AI 成分有限，因与 Chemaxon 同属 Certara 补强而收。本条沿用 R1 的 10-K 出处，二次未重开。"
  },
  {
   "announced": "2023-05-08",
   "closed": "2023-05（具体日期未核）",
   "buyer": "Recursion",
   "target": "Valence Discovery（蒙特利尔）",
   "layer": "a1",
   "layer_name": "小分子",
   "price": "公布 $4750 万（Osler）；Recursion 10-K 记总对价公允价值约 $3590 万",
   "price_disclosed": true,
   "after": "并入 Recursion 数字化学平台（Valence Labs 保留研究团队）。",
   "confidence": "A",
   "target_in_map": false,
   "src": [
    "https://ir.recursion.com/news-releases/news-release-details/recursion-enters-agreements-acquire-cyclica-and-valence-bolster",
    "https://www.osler.com/en/about-us/representative-work/recursion-en/",
    "http://content-archive.fast-edgar.com/20240229/A32ZM22CA222A232222V22E2WWJTZ2228T62/R29.htm"
   ],
   "kind": "收购",
   "note": "两个价格口径不同（宣布价 vs 会计公允价值），都按原文保留。对价为 Recursion 股票、可交换股份与承接期权。"
  },
  {
   "announced": "2023-05-08",
   "closed": "2023-05（具体日期未核）",
   "buyer": "Recursion",
   "target": "Cyclica（多伦多）",
   "layer": "a1",
   "layer_name": "小分子",
   "price": "公布 $4000 万（Osler）；Recursion 10-K 记总对价公允价值约 $6060 万",
   "price_disclosed": true,
   "after": "并入 Recursion，MatchMaker、POEM 模型并入 RecursionOS。",
   "confidence": "A",
   "target_in_map": false,
   "src": [
    "https://ir.recursion.com/news-releases/news-release-details/recursion-enters-agreements-acquire-cyclica-and-valence-bolster",
    "https://www.osler.com/en/about-us/representative-work/recursion-en/",
    "https://betakit.com/american-biotech-recursion-acquires-two-canadian-ai-drug-discovery-companies-cyclica-and-valence/"
   ],
   "kind": "收购",
   "note": "同 Valence。交割日只见预期 2023 Q2。"
  },
  {
   "announced": "2023-01-10",
   "closed": "2023-07-31",
   "buyer": "BioNTech",
   "target": "InstaDeep",
   "layer": "l3",
   "layer_name": "算力与模型托管",
   "price": "公布 £3.62 亿（现金与股票）+ 最高约 £2 亿业绩里程碑；BioNTech 交割稿记剩余股权总对价约 €5 亿",
   "price_disclosed": true,
   "after": "作为 BioNTech 英国子公司继续运营，仍对外服务；建有 Kyber GPU 集群。",
   "confidence": "A",
   "target_in_map": false,
   "src": [
    "https://www.biontech.com/us/en/home/mediaroom/news/press-releases/2023/07/biontech-completes-acquisition-instadeep.html",
    "https://www.actuia.com/en/news/what-has-become-of-instadeep-three-years-after-its-record-takeover-by-biontech/",
    "https://www.bloomberg.com/news/articles/2023-01-10/biontech-said-to-buy-ai-experts-instadeep-for-up-to-562-million"
   ],
   "kind": "收购",
   "note": "边界案例：InstaDeep 是通用决策 AI 公司，对 BioNTech 以药物发现为主，按买方用途归 l3。BioNTech 此前已持股，收购的是剩余 94.7%。"
  },
  {
   "announced": "2022-04-05",
   "closed": "2022-03-31（S&P Capital IQ）",
   "buyer": "Valo Health",
   "target": "TARA Biosystems",
   "layer": "w1",
   "layer_name": "自动化/自驱动实验室",
   "price": "未披露（TARA 股东之一 180 Degree Capital 公告其份额约 $270 万现金 + 最多 $330 万里程碑）",
   "price_disclosed": false,
   "after": "并入 Valo，做心血管疾病的心脏组织模型与 Opal 计算平台垂直整合。",
   "confidence": "A",
   "target_in_map": false,
   "src": [
    "https://www.prnewswire.com/news-releases/valo-health-acquires-tara-biosystems-creating-first-of-its-kind-vertically-integrated-cardiovascular-platform-301517607.html",
    "https://www.globenewswire.com/de/news-release/2022/04/05/2416817/10573/en/180-degree-capital-corp-notes-the-acquisition-of-its-private-portfolio-company-tara-biosystems-inc-by-valo-health-llc.html",
    "https://in.marketscreener.com/quote/stock/180-DEGREE-CAPITAL-34413372/news/Valo-Health-Inc-acquired-TARA-Biosystems-Inc-from-180-Degree-Capital-Corp-Alexandria-Venture-I-39992224/"
   ],
   "kind": "收购",
   "note": "Life Science Nation 博客称「约 $7500 万预付」是单一二手来源，两份一手材料都没有总价，未采用。"
  },
  {
   "announced": "2021-08",
   "closed": "2021-08（创始人说法）",
   "buyer": "Genentech（Roche）",
   "target": "Prescient Design",
   "layer": "a2",
   "layer_name": "抗体与蛋白药",
   "price": "未披露",
   "price_disclosed": false,
   "after": "聚焦抗体设计，做 lab-in-the-loop 抗体设计。",
   "confidence": "A",
   "target_in_map": false,
   "src": [
    "https://www.nature.com/articles/d43747-023-00020-4",
    "https://iclr.cc/virtual/2024/invited-talk/21801"
   ],
   "kind": "收购",
   "note": "公司 2021-01 成立。月份来自创始人在 ICLR 的讲者介绍和 Nature 特写，宣布日未找到公告。"
  },
  {
   "announced": "2021-06-15",
   "closed": "2021-06（未核具体日；Crunchbase 页面仍标 pending）",
   "buyer": "Exscientia",
   "target": "Allcyte（维也纳）",
   "layer": "a1",
   "layer_name": "小分子",
   "price": "报道称 €5000 万，现金加 Exscientia 普通股（World Pharmaceutical Frontiers）",
   "price_disclosed": true,
   "after": "并入 Exscientia 做患者样本药敏筛选平台；随 Exscientia 一起并入 Recursion 体系（2024-11）。",
   "confidence": "A",
   "target_in_map": false,
   "src": [
    "https://www.worldpharmaceuticals.net/news/exscientia-acquires-precision-medicine-company-allcyte-for-e50m/",
    "https://pharmatimes.com/news/exscientia_expands_translational_capabilities_with_allcyte_acquisition_1371698/",
    "https://brandltalos.com/en/insight/brandl-talos-advised-shareholders-of-allcyte-on-sale-to-exscientia/"
   ],
   "kind": "收购",
   "note": "R1 里只有聚合站的 $5400 万已弃用，改用媒体报道的 €5000 万；公司稿只披露「binding agreement」。多源但价格未见一手，故价格栏写「报道称」。"
  },
  {
   "announced": "2021-06-14",
   "closed": "2021-06（SEC 备考报表；具体日未核）",
   "buyer": "Absci",
   "target": "Totient",
   "layer": "a2",
   "layer_name": "抗体与蛋白药",
   "price": "SEC 备考：估计总对价约 $5986 万（现金 $3537 万 + 股票 $1389 万 + 或有现金 $1060 万）",
   "price_disclosed": true,
   "after": "成为 Absci 全资子公司，补抗体与靶点发现；合并协议签于 2021-06-04，2025-10 双方清算托管资金，确认无后续付款。",
   "confidence": "A",
   "target_in_map": false,
   "src": [
    "https://www.sec.gov/Archives/edgar/data/1672688/000162828021013857/abscis-1a2.htm",
    "https://www.vivabiotech.com/news/578.html",
    "https://contracts.justia.com/companies/absci-corp-13368/contract/1345798/"
   ],
   "kind": "收购",
   "note": "卖方含 Viva Biotech 旗下基金。边界案例：Absci 是 AI 抗体设计公司，Totient 做人源抗体与靶点发现。"
  }
 ]
}